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Abstract  MRI-guided  biopsy  is  a  recent  interventional  breast  technique.  Validating  the  pro-
cedure poses  a  new  problem  because  the  signal  targeted  is  created  by  the  injection  of  a
paramagnetic  contrast  agent  and  is  thus  transitory.  In  the  ﬁrst  instance,  the  procedure  is  vali-
dated by  the  radiologist,  who  checks  that  targeting  is  accurate  and  inserts  a  clip  at  the  end  of
the procedure,  and  secondly  by  analysis  of  the  histopathological  results,  which  should  be  rep-
resentative  of  the  lesion.  The  pathologist  needs  to  know  the  nature  of  the  image,  i.e. whether
it is  of  mass  or  non-masslike  enhancement,  and  its  BI-RADS  classiﬁcation.  The  objective  is  that
the image  and  the  pathological  result  should  concur.  If  the  result  is  non-speciﬁc  and  benign,  a
follow-up MRI  is  required  six  months  later.
© 2013  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Introduction: an overview of MRI-guided biopsy
General points
Breast  MRI  can  detect  cancers,  which  are  occult,  both  clinically  and  in  mammography
examinations.  The  sensitivity  of  the  technique  has  been  evaluated  at  between  94  and
100%  but  its  speciﬁcity  is  more  variable,  at  between  37  and  97%  [1]. Histopathological
evidence  needs  to  be  obtained  to  detect  an  indeterminate  or  suspect  lesion  in  MRI  [1].
MRI-guided  biopsy  can  conﬁrm  its  nature,  but  before  deciding  on  this  course  of  action,  it
is  essential  to  check  the  uptake  of  contrast  by  ultrasound  or  mammography.  MRI-guided
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iopsy  is  still  an  uncommon  examination  because  of  limited
ccess  to  machines,  the  time  it  takes,  the  cost  of  the  mate-
ial  and  the  discomfort  for  the  patient.  Three  types  of  MRI
nhancing  lesions  are  described  by  the  BI-RADS  classiﬁca-
ion  [2]:
a  mass  (a  process  occupying  a  space),  the  rationale  for
radiopathological  correlation  being  comparable  with  that
for  a  mass  detected  by  ultrasound  or  mammography;
non-masslike  enhancement  (MRI  contrast  uptake  occu-
pying  the  space  of  the  normal  gland  but  without  mass
effect),  this  image  essentially  being  generated  by  the
injection  of  a  paramagnetic  contrast  agent;
a  focus  (an  area  of  contrast  uptake  measuring  less  than
5  mm).
The  last  two  types  of  lesion,  which  are  described  only  in
agnetic  resonance  imaging,  raise  a  new  problem  for  vali-
ating  the  correlation  between  the  image  targeted  and  the
athological  diagnosis  obtained.  MRI-guided  biopsy  needs  to
e  fully  understood,  to  grasp  the  problem.
ndication for an MRI-guided biopsy
ypes  of  lesion
RI  mass  or  non-masslike  enhancements  (NMLE)  classed  in
he  BI-RADS  categories  4  or  5  are  biopsied,  as  are  those
lassed  3  by  BI-RADS  detected  in  a  patient  being  monitored
or  high  familial  risk.  The  positive  predictive  value  of  these
esions  is  higher  in  this  group  of  patients.
The  indication  will  be  determined  after  eliminating
false’  contrast  uptake,  related  to  physiological  glandular
nhancement  in  a  pre-menopausal  patient  examined  dur-
ng  the  2nd  part  of  her  cycle,  or  of  hormonal  origin  in  a
atient  receiving  hormone  treatment.  In  these  situations,
he  MRI  will  be  repeated  to  conﬁrm  the  persistent  and  there-
ore  pathological  nature  of  the  abnormal  enhancement.
RI-guided  biopsy  is  also  indicated  after  any  signs  of  these
nhancements  in  conventional  imaging  (mammography  and
ltrasound)  have  been  eliminated.
orrelation  with  conventional  imaging
hen  there  is  positive  correlation  with  a  conventional
maging  examination,  a  histopathological  diagnosis  can  be
btained  by  ultrasound-guided  microbiopsy,  if  the  lesion
s  visible  with  ultrasound,  or  by  stereotactic  macrobiopsy
here  there  is  only  mammographic  detection.
econd  look  ultrasonography
he  literature  shows  that  the  efﬁcacy  of  second  look  ultra-
onography  is  very  variable,  ranging  from  23  to  89%  [3].  It  is
ot  easy  to  perform  since  it  depends  on  detecting  subtle  or
mall  images  not  usually  revealed  in  a  standard  ultrasound
xamination.  The  radiologist  needs  to  know  the  information
rom  the  MRI  and  how  to  interpret  all  breast  examination
echniques:  mammography,  ultrasound  and  MRI.  MRI  is  best
ead  on  the  console  so  that  the  type  of  enhancement,  its
ize  and  precise  location  can  be  evaluated.  With  second  look
ltrasound,  the  lesion  can  be  found  and  ultrasound-guided
iopsies  performed  in  more  than  50%  of  cases.  Ultrasound
orrelation  is  most  often  found  for  mass  enhancements,
hereas  it  is  less  frequent  in  the  case  of  non-masslike
nhancement  or  a  focus  [4].  Certain  authors,  for  example
a
n
b
cJ.  Chopier  et  al.
aTrenta  et  al.,  have  shown  that  when  these  lesions  can
e  detected  with  ultrasound  this  tends  to  indicate  their
alignant  nature  (43%  versus  14%)  [5]. Similarly,  the  risk
f  a  malignant  lesion  is  higher  if  the  latter  is  in  the  same
uadrant  of  the  breast  as  a conﬁrmed  neoplastic  lesion.
argeted  rereading  of  the  mammogram
ocalized  and  enlarged  images  should  be  made  centered
n  the  area  of  the  breast  where  the  MRI  abnormality  has
een  found.  If  a  group  of  microcalciﬁcations,  distortion
r  asymmetry  is  found  that  is  not  visible  on  the  standard
mage,  stereotactic  biopsy  might  be  performed.  Thomassin-
aggara  et  al.  have  shown  the  importance  of  detecting
icrocalciﬁcations  combined  with  NMLE  in  MRI  [6]. In  this
ase,  the  PPV  is  90%  for  enhancement  measuring  more  than
0  mm.  This  author  has  also  conﬁrmed  the  high  PPV  of  multi-
le,  regional,  diffuse,  asymmetric,  segmentally  distributed
MLEs,  or,  where  these  signs  are  absent,  that  age  of  more
han  44  years  increases  the  PPV  of  detected  non-masslike
nhancements  [6].
ynthesis
t  is  essential  to  conﬁrm  concordance  with  the  ultrasound
r  mammogram  image  by  inserting  a  clip  at  the  end  of  the
ltrasound-guided  microbiopsy  or  the  stereotactic  macro-
iopsy.  If  there  is  any  doubt  about  the  accuracy  of  targeting,
 T2*-weighted  MRI  sequence  can  be  obtained,  to  conﬁrm  it
y  checking  the  position  of  the  clip  relative  to  the  site  of  the
RI  enhancement  and  possibly  the  site  of  the  hematoma.
o  correlation  with  conventional  imaging
he  lack  of  ultrasound  or  mammographic  correlation  is  not
rm  evidence  of  the  benign  nature  of  a  lesion.  According  to
arious  published  studies,  a cancer  is  conﬁrmed  in  14  to  57%
f  cases  of  MRI  lesions  without  ultrasound  correlation:  in  this
ituation  those  more  frequently  encountered  are  carcinomas
n  situ  and  invasive  lobular  carcinomas  [3].
At  6%,  the  positive  predictive  value  of  MRI  lesions  in
he  BI-RADS  3  class  (probably  benign)  is  higher  than  for
onventional  imaging,  with  less  than  or  equal  to  2%  in  mam-
ography  or  ultrasound  [2,7].  The  action  to  be  taken  is  as
ollows  for  BI-RADS  3  lesions:  If  there  is  a  concomitant  malig-
ant  lesion  an  MRI-guided  biopsy  is  performed  without  delay.
n  a  high  risk  context  an  early  follow-up  MRI  is  scheduled
fter  4  months  and  a  biopsy  performed  if  the  image  persists
r  has  increased  in  size.  Apart  from  these  particular  situa-
ions,  there  should  be  an  MRI  follow-up  at  6  months  and  a
iopsy  performed  if  the  lesion  has  increased  in  size.  For  BI-
ADS  4  or  5  lesions,  MRI-guided  biopsy  is  essential  and  must
e  organized  without  delay.
ype of material used: coil and needle
he  surface  coil  must  both  allow  access  to  the  breast  and
old  it  by  a  compression  system;  most  systems  use  an  inter-
al  or  external  lateral  approach  (Fig.  1).  The  system  most
ften  used  consists  of  a  compression  grid  into  which  a  mul-
iply  perforated  sterile  guide  block  is  inserted.  This  block
cts  as  a  support  and  guide  for  the  coaxial  sheath  and
eedle.  After  dynamic  contrast-enhanced  sequences  have
een  performed  to  locate  the  lesion,  its  coordinates  are
alculated  and  a  cannula  placed  in  the  sheath  (Fig.  2).  A
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Figure 1. MRI-guided biopsy coil for a lateral approach with
compression grid.
Figure 4. Macrobiopsy needle in place for performing the biopsy
through the grid.
F
q
mFigure 2. Compression grid with guide block system, coaxial
sheath in place.
sequence  without  injection  conﬁrms  that  targeting  is  cor-
rect  (Fig.  3a,  b).  The  samples  are  taken  with  large  gauge
needles  (11-7  G)  attached  to  an  aspiration  system  (aspiration
macrobiopsy)  (Figs.  4  and  5).  The  advantages  are  that  good
a
(
s
Figure 3. Sagittal contrast-enhanced MRI breast sequence before MRI-
without enhancement to check the position of the tip of the cannula befigure 5. Specimens obtained after MRI-guided biopsy.
uality  histological  samples  are  rapidly  obtained,  the  equip-
ent  is  relatively  inexpensive  and  the  biopsy  does  not  leave
 scar.  The  recommendations  are  that  at  least  18  samples
11G)  should  be  obtained  and  that  a  clip  should  be  inserted
ystematically  at  the  end  of  the  procedure  [8].
guided biopsy: a: location of the mass to be biopsied; b: sequence
ore performing the biopsy.
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istopathological results and
adiopathological correlation
articular issues concerning MRI-guided biopsy
echnical  limitations  of  MRI-guided  biopsy
ince  the  magnets  are  more  often  enclosed,  the  biopsy
amples  must  be  obtained  outside  of  the  magnet.  The
atient’s  procubitus  position  can  hamper  access  to  the
esion.  The  approach  to  prepectoral,  retroareolar  or  super-
cial  lesions  is  difﬁcult  or  impossible.  Insufﬁcient  breast
hickness  remains  a  limiting  technical  factor.  The  effect
f  compression  by  the  grid  may  reduce  the  intensity  and
s
n
o
igure 6. Contrast-enhanced breast MRI: a: axial slice: examination b
agittal scout slice during the biopsy: the contrast uptake is less clearly 
igure 7. Contrast-enhanced breast MRI: a: axial slice. BI-RADS 4 co
alignant lesion of the contralateral breast; b: sagittal scout slice before
argeted; c: sagittal scout slice before the biopsy: contrast uptake corre
ith the initial MRI images.J.  Chopier  et  al.
mount  of  contrast  uptake  in  comparison  with  the  previous
RI  that  led  to  the  biopsy  (Fig.  6a,  b),  hence  the  importance
f  having  the  previous  MRI  available  on  a  console  during
he  biopsy  to  ensure  adequate  targeting  by  comparing  the
osition  and  type  of  contrast  uptake  of  both  examinations
Fig.  7a,  b,  c).  Sometimes  no  contrast  uptake  is  found  dur-
ng  the  pre-biopsy  scout  sequence.  Liberman  et  al.  reported
hat  12%  of  lesions  referred  for  a  biopsy  did  not  enhance
n  the  examination  [9]. A  follow-up  MRI  was  performed  for
3%  of  these  lesions  and  more  than  half  of  the  examinations
howed  no  enhancement.  Heﬂer  et  al.  reported  a  malig-
ancy  rate  of  10%  for  lesions  which  were  no  longer  visible
n  the  day  of  the  biopsy,  but  which  were  seen  again  in  the
efore the biopsy showing a left lateral spiculated mass (arrow); b:
visible and reduced to a punctiform lesion.
ntrast uptake of the left breast of a patient with a history of a
 the biopsy: ‘false’ contrast uptake not corresponding to the lesion
sponding to the lesion to be biopsied, recognized after comparison
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and  malignancy  rates  between  27  and  37%  for  most  series
[11—17], and  higher  in  two  series  [14,17].  The  latter  results
are  explained  by  the  differences  in  the  populations  stud-
ied,  including  more  high  risk  patients  in  one  [17]  and  more
MRIs  performed  in  staging  a  malignant  condition  in  the  other
[14]. Figures  reported  for  atypical  lesions  were  from  7  to  21%
depending  on  the  authors  (Table  2) [17—19],  the  percent-
age  of  their  underestimation  of  12—25%  in  the  most  recent
series  corresponding  to  atypical  lesions  that  proved  to  be
malignant  on  surgery  (Table  2).  For  some  authors,  this  under-
estimate  also  corresponded  to  the  number  of  carcinomas
in  situ, which  were  upgraded  to  invasive  carcinoma  after
surgery  [18]. Nevertheless,  the  importance  is  noted  of  addi-
tional  surgery  following  macrobiopsies  indicating  high-risk
lesions,  because  30%  of  these  lesions  operated  in  Rauch’s
series  were  cancers  [18].  In  certain  series,  higher  ﬁgures,
of  30  to  50%,  are  reported  for  underestimating  high-risk
lesions  [9,20,21]. These  high-risk  lesions  include  papillary
lesions,  which  are  also  recommended  for  surgery  where  the
diagnosis  is  obtained  by  MRI-guided  biopsy,  because  the  ﬁg-
ures  reported  for  underestimating  them  were  9%  in  the  case
of  atypia  combined  with  the  papillary  lesion  and  5%  in  the
absence  of  atypia  [22].
Factors inﬂuencing the results
According  to  the  type  of  image:  mass  or
non-masslike  enhancement
The  malignancy  rate  is  higher  when  the  lesion  biopsied  using
MRI  is  a  mass  rather  than  an  NMLE,  assessed  respectively  at
34—60%  and  27-41%  [17,19,23].
Table  2 Rates  of  underestimation  of  atypical  lesions  in
MRI-guided  biopsies.
Studiesa Atypiab Underestimationc
Han,  2008  (19) 14  (150) 25
Malhaire,  2010  (17) 14  (72)  13
Rauch,  2012  (18) 17  (37) 12
aRadiopathological  correlations  
follow-up  MRI  [10].  A  follow-up  MRI  shortly  afterward  is  sug-
gested  therefore  when  a  lesion  considered  to  be  potentially
suspect  is  not  visible  on  the  day  of  the  biopsy.
Difﬁculty  obtaining  the  sample
The  MRI  lesion  justifying  the  biopsy  is  located  because  it
takes  up  the  contrast  agent.  The  target  is  not  constant
over  time  however,  because  the  enhancement  attenuates
after  the  injection,  making  it  difﬁcult  to  locate.  Physio-
logical  enhancement  of  the  breast  tissue  adjacent  to  the
lesion  can  hinder  identiﬁcation  of  the  target.  Compression
reduces  the  intensity  and  size  of  the  lesion  by  reducing  its
vascularization  (Fig.  6  a,  b)  and  this  can  hinder  locating  it.
Radiopathological  correlation  remains  the  major  problem,
rendered  difﬁcult  by  the  absence  of  ‘ex  vivo’ evidence  of
the  MRI  enhancement.  The  sample  can  only  be  conﬁrmed  as
adequate  later.  In  contrast,  stereotactic  biopsies  are  val-
idated  immediately  by  the  presence  of  calciﬁcations  on
the  x-ray  image  of  the  samples,  or,  with  ultrasound  guid-
ance,  in  real  time  by  viewing  the  point  of  the  needle  in
the  lesion  along  two  orthogonal  axes.  The  main  drawback
of  MRI-guided  biopsy  is  that  it  is  impossible  to  conﬁrm  that
the  lesion  is  actually  present  in  the  specimens  collected  in
real  time  during  the  biopsy,  hence  the  importance  of  the
radiologist  validating  the  quality  of  the  targeting  and  the
pathologist  checking  the  representative  character  of  the
samples  [3].
Diagnostic performance
The  largest  study  on  the  subject,  reported  by  Perlet  et  al.
and  published  in  2006,  was  a  multicenter  study  concerning
538  biopsied  lesions;  27%  were  malignant  lesions,  3%  atypical
and  70%  benign  lesions.  The  biopsy  was  performed  success-
fully  in  98%  of  cases.  Size  does  not  seem  to  be  a  limiting
factor  since  the  biopsies  were  performed  successfully  in  96
and  97%  of  cases  respectively  for  lesions  smaller  than  or
larger  than  10  mm.  The  mean  duration  of  the  procedure
was  70  min  for  one  lesion  and  90  min  for  two  lesions  [11].
There  were  rare  hemorrhagic  or  infectious  complications
comparable  with  those  described  for  macrobiopsies  per-
formed  with  another  guidance  method.  The  other  studies
published  on  the  subject  (Table  1)  report  an  equivalent  diag-
nostic  performance  with  96—100%  success  of  the  technique
Year of publication (reference).
b Atypia rate as % (number of biopsies, absolute value).
c Underestimation rate as %.
Table  1  Rates  of  success  of  MRI-guided  biopsies  and  percentage  of  malignancy.
Studiesa Technical  success  rateb Malignancy  ratec False  negativesd
Malhaire,  2010  (17)  72/74  (97)  33/72  (46)  2
Fischer,  2009  (16)  365/389  (96)  106/365  (27)  2  (immediate)
Perlet,  2006  (11)  517/538  (96)  138/517  (27)  0
Gebauer,  2006  (515)  42/42  (100)  11/42  (26)  1  (immediate)
Orel,  2006  (514)  85/85  (100)  52/85  (61)  2  (immediate)
Liberman,  2005  (13) 95/98  (97)  24/98  (25)  7  (incl.  3  atypia)
Lehman,  2005  (12)  38/38  (100)  14/38  (37)  1  (atypia)
a Year of publication (reference).
b Number of successful procedures/number of procedures (success rate %).
c Number of cancers/total biopsies (malignancy rate %).
d False negatives as absolute value.
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Of  the  descriptive  points  characterizing  NMLEs,  their  duc-
al  or  segmental  distribution  has  the  highest  PPV,  reported
espectively  as  26—37%  and  30—50%,  depending  on  the  series
17—19].  The  high  PPV  for  focal  NMLEs,  reported  as  50%  in
heir  series  by  Malhaire  et  al.,  was  not  found  in  the  other
eries  [17].
As for  masses,  their  having  irregular  or  spiculated  con-
ours  have  a  PPV  of  between  27  and  43%  [18,19].  According
o  Han  et  al.,  no  morphological  or  dynamic  characteristic
as  any  statistically  signiﬁcant  value;  nevertheless,  the  risk
f  malignancy  would  seem  to  be  higher  when  the  mass  has
rregular  contours  and  a  type  2  or  3  dynamic  curve,  or  when
he  mass  has  regular  contours  combined  with  a  type  3  curve
19].
he  size  of  the  image
n  the  recent  series  reported,  the  mean  size  of  the
esions  biopsied  could  be  compared  with  a  mean  of  12  mm
4—70  mm)  in  Malhaire  et  al.’s  series  and  15  mm  in  Han’s
4—70  mm)  [17,19].  It  appeared  that  the  mean  size  of  lesions
iopsied  is  greater  for  non-masslike  enhancements  than  for
asses,  16  mm  versus  10  mm  [17].  The  incidence  of  cancer
ncreases  with  the  size  of  the  lesion  detected  using  MRI;  it
eems  to  be  3%  for  lesions  of  less  than  5  mm  as  against  31%
or  lesions  of  20  mm  and  more  [24].  However,  more  recent
eries  conﬁrm  the  need  for  MRI-guided  biopsy  exploration  of
ny  suspect  contrast  uptake,  even  if  it  is  less  than  or  equal
o  5  mm  in  size,  because  in  certain  series  their  PPV  is  20—31%
25,26].  This  is  particularly  so  for  the  group  of  patients  for
hom  MRI  was  indicated  for  staging  a  malignant  lesion;  if
he  contrast  uptake  was  in  the  same  breast,  the  PPV  was
7.8%,  in  the  same  quadrant  44.4%  and  in  the  contralateral
reast  16.7%  [25,26].
oexistence  of  other  lesions
ssociation  with  a  malignant  lesion  concomitant  to  the  con-
rast  uptake  detected  raises  its  PPV,  which  reached  43%  in
he  series  by  Han  et  al.  when  the  cancer  was  homolateral,
nd  30%  when  the  cancer  was  in  the  contralateral  breast
19].  Similar  ﬁgures  have  been  reported  by  other  authors
18,27].
i
q
t
t
igure 8. Contrast-enhanced breast MRI: a: contrast-enhanced control
he contrast agent mixed with the hematoma; b: sagittal slice after MRI-
ignal mixing with residual contrast uptake.J.  Chopier  et  al.
he  indication  for  MRI
he  probability  of  malignancy  varies  depending  on  the  indi-
ation  for  MRI.  It  was  36  and  28%,  respectively,  in  Han’s
nd  Rauch’s  series,  in  the  group  of  women  who  underwent
RI  for  staging  a  malignant  lesion  or  for  evaluating  a  clin-
cal  problem.  The  PPV  is  lower,  at  14  and  10%  respectively
or  these  two  authors,  when  MRI  is  performed  for  screening
18,19].
echnique for validating the procedures
his  poses  two  major  questions  concerning  targeting  and
adiopathological  correlation.  For  the  ﬁrst,  the  question  is
hether  the  biopsy  has  been  taken  at  the  right  place.  For
he  second,  it  is  whether  the  samples  are  sufﬁcient  to  allow
he  pathologist  to  correlate  the  MRI  image  with  what  is  rep-
esented  on  his  slides  of  the  pathology.
mmediate  validation  of  targeting
or  some  authors,  disappearance  of  the  abnormal  con-
rast  uptake  after  the  biopsy  can  be  validated  with  an  MRI
equence  after  reinjecting  contrast  agent  at  the  end  of  the
rocedure  [11].  However,  in  current  practice,  suffusion  of
he  contrast  agent  due  to  vascular  breakdown  together  with
emorrhagic  changes  does  not  conﬁrm  with  any  certainty  a
eduction  in  size  of  the  contrast  uptake  targeted  (Fig.  8a,
).  Other  authors  suggest  a  follow-up  MRI  after  24  h,  demon-
trating  that  in  nearly  14%  of  cases  the  lesion  would  not  have
een  correctly  targeted  [28].  A  non  contrast-reenhanced  MRI
equence  with  3-dimensional  reformatting  performed  at  the
nd  of  the  procedure  currently  conﬁrms  that  the  biopsy  cav-
ty  and  the  clip  are  perfectly  centered  in  the  targeted  area
Fig.  9).  If  there  is  any  doubt  about  the  quality  of  target-
ng,  a  follow-up  MRI  performed  8—15  days  later  can  provide
eriﬁcation.
adiopathological  correlation
he  procedure  is  validated  when  the  pathological  diagnosis
s  obtained;  it  answers  the  two  questions  concerning  the
uality  of  the  targeting  and  the  material  provided  to
he  pathologist.  Radiopathological  correlation  conﬁrms  that
he  diagnosis  obtained  is  consistent  with  the  image  targeted
 sagittal slice after the biopsy: post biopsy changes with suffusion of
guided biopsy: gas ﬁlled cavity with hematoma with a hyperintense
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Figure 9. Contrast-enhanced breast MRI, checking the position
F
e
dof the biopsy cavity in the three planes by reformatting, allowing
comparison with the series produced before the biopsy.
and  its  level  of  diagnostic  assumption  [29].  For  masses,  the
suspicious  MRI  signs  are  spiculated  or  irregular  margins,  rim
enhancement  and  a  type  3  enhancement  curve,  even  if  sus-
picious  morphological  criteria  are  absent,  while  for  NMLEs,
they  are  their  segmental  or  ductal  distribution,  their
multinodular  or  multiple  rim  character  [17—19]
(Figs.  10  and  11a,  b).
g
•
Figure 11. Contrast-enhanced breast MRI: a: multinodular regional no
non-masslike enhancement. BI-RADS 4C.
Figure 12. a: contrast-enhanced breast MRI: axial slice. Contrast upt
tralateral to a multifocal cancer of the right breast; b: HES × 2.5 histolog
the left breast, a grade II inﬁltrating ductal adenocarcinoma. Concordanigure 10. Contrast-enhanced breast MRI: BI-RADS 5 mass
nhancement showing spiculated margins.
Various  categories  of  radiopathological  concordance
escribed  for  imaging-guided  biopsies  can  be  applied  to  MRI-
uided  biopsies  [30]:
category  1:  concordance  concerning  malignancy:  suspect
images,  malignant  histology  (Figs.  12  and  13);
n-masslike enhancement. BI-RADS 4C; b: heterogeneous segmental
ake in suspect mass with irregular margins in the left breast con-
ical section corresponding to the MRI-guided biopsy of the mass in
t result: suspect images and malignant result; surgery is necessary.
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Figure 13. a: contrast-enhanced breast MRI: axial slice. Contrast uptake of a mass combined with distortion in a situation (arrow)
p ma in situ; MRI-guided biopsy decided; b: HES × 2.5 histological section
c ast. Mixed ductal/lobular adenocarcinoma. Concordant result: suspect
i
•
•
•
Figure 14. Contrast-enhanced breast MRI: axial slice. Contrast
uptake of focal non-masslike enhancement, classed as BI-RADS 4a,
in a patient treated for ovarian cancer; MRI-guided biopsy: invasive
l
m
F
H
costerior to a malignant lesion already proved to be ductal carcino
orresponding to the MRI-guided biopsy of the mass in the right bre
mages and malignant result; surgery is necessary.
category  2:  discordance  concerning  malignancy,  with
benign  images  and  malignant  histology.  In  this  situation,
the  pathologist  must  be  asked  to  conﬁrm  the  result  and  if
necessary  the  imaging  should  be  reviewed  to  avoid  under-
estimating  the  severity  of  the  lesion  (Fig.  14);
category  3:  concordance  concerning  the  benign  nature;
benign  images  and  benign  histology  for  BI-RADS  2  to  BI-
RADS  4a  lesions.  The  histopathological  results  obtained
may  not  be  very  speciﬁc:  ﬁbrocystic  mastopathy,  for
which  it  is  best  to  have  the  pathologist  specify  the  basic
lesions  and  the  proliferative  (presence  of  regular  ductal
hyperplasia  and  its  severity)  or  non-proliferative  charac-
teristics  (apocrine  metaplasia,  sclerosing  adenosis,  focal
ﬁbrosis)  (Fig.  15a,  b).  In  all  these  cases,  comparison  with
the  adjacent  breast  tissue  and  specifying  the  lesion’s
focalized  character,  or  otherwise,  is  useful  for  validating
correlation  with  imaging.  Sometimes,  the  lesion  appears
more  speciﬁc  because  it  is  localized,  such  as  a  ﬁbroade-
noma,  a  lymph  node  or  fat  necrosis  (Fig.  16a,  b).  Finally,
the  signals  may  also  be  due  to  localized  enhancement  of
normal  parenchyma.  In  all  these  situations  MRI  follow-up
at  6  months  is  recommended  (Fig.  17a,  b);
category  4:  discordance,  with  suspect  images  (BI-RADS
4  or  5)  and  benign  histology.  In  imaging,  certain  benign
lesions  can  simulate  a  cancer  due  to  their  localized  char-
acter,  and/or  their  cellularity  and/or  their  association
igure 15. a: contrast-enhanced breast MRI: sagittal slice. Contrast u
ES × 10 histological section corresponding to the MRI-guided biopsy of
ontext of sclerocystic mastitis. Concordant benign but not very speciﬁcobular carcinoma and lobular carcinoma in situ. Benign images but
alignant results; surgery necessary.
with  ﬁbrosis  or  inﬂammation  and/or  their  vascularization,
and/or  because  they  disrupt  the  normal  architecture  of
breast  tissue,  as  in  sclerosing  adenosis,  complex  scleros-
ing  lesions,  fat  necrosis,  granular  cell  tumors,  surgical
ptake of heterogeneous regional NMLE, classed as BI-RADS 4a; b:
 the regional NMLE; ﬂorid ductal hyperplasia without atypia in a
 result requiring a follow-up MRI after 6 months.
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Figure 16. a: contrast-enhanced breast MRI: axial slice. Contrast uptake of mass with a benign appearance in the right breast in an
axillary ACUP; b: HES × 2.5 histological section corresponding to the MRI-guided biopsy of the mass in the right breast, ﬁbroadenoma with
intraductal architecture. Benign concordant result. No follow-up.
Figure 17. a: contrast-enhanced breast MRI: axial slice. Contrast uptake of an oval mass with rim enhancement contralateral to a
multifocal carcinoma of the left breast. Classed as BI-RADS 4B; b: HES × 2.5 histological section corresponding to the MRI-guided biopsy of
sia. Bthe mass in the left breast: focus of adenosis in apocrine metapla
6 months.
scars,  mastitis,  diabetic  mastopathy,  or  sarcoidosis.  How-
ever,  because  of  the  risk  of  missing  a  malignant  lesion,  it  is
important  to  propose  another  biopsy  or  surgery  (Fig.  18a,
b);
• category  5:  high-risk  lesions  (atypical  ductal  hyperplasia,
lobular  neoplasia,  papillary  lesion,  phyllodes  tumor),  for
which  additional  surgery  is  recommended  because  of  the
d
U
Figure 18. a: contrast-enhanced breast MRI: axial slice. Contrast up
classed as BI-RADS 4C (arrow); b: HES × 10 histological section correspo
ﬁbrosis, punctuated by siderophages, compatible with a scar lesion (no
benign histological results; another biopsy or surgery suggested.enign result but suspicious imaging, requiring MRI follow-up after
known  risk  of  underestimation  with  other  percutaneous
breast  biopsy  techniques  (ultrasound-guided  or  stereotac-
tic  microbiopsies  and  macrobiopsies)  (Fig.  19a,  b).Radiopathological  correlation  for  MRI-guided  biopsies  is
ifﬁcult  to  establish,  in  particular  when  evaluating  NMLEs.
nlike  stereotactic  macrobiopsies  on  microcalciﬁcations,
take of segmental NMLE contralateral to a multifocal carcinoma
nding to the MRI-guided biopsy of the NMLE: rather non-speciﬁc
 known breast history). Discordant result with suspect images and
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Figure 19. a: contrast-enhanced breast MRI: sagittal slice. Homogeneous focal NMLE contrast uptake classed as BI-RADS 4a; b: HES × 10
h NMLE
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ex  vivo  validation  of  the  reliability  of  the  biopsyistological section corresponding to the MRI-guided biopsy of the 
umor proliferation. Concordant result in all the high-risk lesions bi
here  the  presence  of  the  calcium  in  the  radiological  signal
nd  histologically  in  the  samples  can  validate  the  procedure,
r  even  in  the  biopsy  of  a  mass  where  the  nodular  char-
cter  of  the  lesion  can  be  recognized  by  the  pathologist,
uring  analysis  of  macrobiopsies  relating  to  an  NMLE  there
re  currently  no  speciﬁc  aspects  that  allow  the  pathologist
o  conﬁrm  that  the  samples  have  been  perfectly  targeted.
For  the  radiologist,  validating  an  MRI-guided  biopsy
herefore  consists  of  ensuring  that  the  biopsy  samples  have
een  collected  from  the  correct  target  by  producing  doc-
ments  imaging  the  procedure,  providing  the  pathologist
ith  the  level  of  diagnostic  assumption  concerning  the
mage  using  the  BI-RADS  classiﬁcation  of  the  lesion,  in  addi-
ion  to  detailing  certain  signs,  in  particular  those  with  the
ighest  PPV,  and  familiarizing  the  pathologist  with  the  clas-
iﬁcation  of  this  new  set  of  radiological  signs  with  which
e  is  as  yet  unfamiliar.  All  this  information  will  help  the
athologist  to  recognize  a  predominant  lesion  representa-
ive  of  the  condition  when  examining  the  tissue  provided,
nd  to  distinguish  it  from  the  normal  tissue.  As  for  all
iopsies,  lesion  fragmentation  may  hinder  the  pathologist.
t  is  important  for  the  pathologist  to  deﬁne  the  normal
reast  histology  depending  on  the  age  of  the  patient,  her
enopausal  status  (richness  in  lobules  and  their  size)  and
ny  hormone  treatment,  and  also  perhaps  to  know  the
natomical  area  from  which  the  samples  have  been  taken:
n  the  middle  of  glandular  parenchyma  or  at  the  fat/gland
nterface.
For  MRI-guided  biopsies,  this  correlation  is  still  difﬁcult
nd  at  present  there  are  no  data  in  the  literature  of  speciﬁc
tudy  of  this  aspect.  Consequently  a  follow-up  MRI  some
ime  later  seems  essential  in  particular  where  there  are
enign,  non-speciﬁc  histological  results  and  benign  images
category  3).  Of  the  results  considered  to  be  benign  and
oncordant,  Sung  et  al.  found  8—12%  of  the  lesions  had  been
nadequately  biopsied,  with  a  rate  of  malignancy  assessed
t  between  14—18%,  i.e.  an  estimated  rate  of  false  nega-
ives  of  2.5%  [29].  A  follow-up  MRI  at  6  months  is  offered  in
he  event  of  benign  and,  at  ﬁrst  sight,  concordant  results
29].  If  at  the  time  of  this  follow-up  the  lesion  appears  to
e  stable  in  size,  it  is  recommended  to  continue  monitoring
or  2  years,  although  in  the  series  by  Li  et  al.,  two  lesions
table  at  2  years  were  later  found  to  be  malignant  [31].
f  the  size  of  the  lesion  has  increased  at  follow-up  a new: classic lobular carcinoma in situ, distended lobules ﬁlled by the
d and surgery proposed.
RI-guided  biopsy  or  surgery  must  be  proposed.  If  the  lesion
as  decreased  in  size  or  disappeared,  monitoring  may  be
iscontinued.
onclusion
RI-guided  biopsy  is  a  technique  that  is  becoming  more
idespread.  The  technical  difﬁculties  of  the  procedure
ave  currently  been  overcome  through  improvement  in
he  equipment.  The  difﬁculty  remaining  concerns  the  reli-
bility  of  the  radiopathological  correlation,  because  the
iopsy  signal  is  unusual,  being  revealed  by  enhancement
ollowing  the  injection  of  a  paramagnetic  contrast  agent;
n  addition  this  image  is  only  transitory.  The  reliability
f  a benign  result  more  often  than  not  revealing  a  non-
peciﬁc  condition  should  always  be  discussed  fully  in  a
ultidisciplinary  consultative  meeting.  Improvement  in  the
eliability  of  this  concordance  is  desirable  and  requires
urther  studies.  Currently,  only  later  monitoring  of  the
iopsied  lesion  can  provide  certainty  by  showing  its  sta-
ility  or  decrease  in  size.  For  malignant  results  or  those
howing  a  high-risk  lesion,  surgery  is  currently  recom-
ended.
TAKE-HOME  MESSAGES
General  concepts
• MRI-guided  biopsy  is  a  new  interventional  breast
imaging  technique,  which  is  still  not  common.
• Lesions  classed  as  BI-RADS  4  or  5  in  MRI,  or  even
BI-RADS  3  in  a  context  of  high  risk,  undergo  MRI-
guided  biopsy  once  the  presence  of  an  ultrasound  or
mammographic  equivalent  of  the  enhancement  has
been  eliminated  in  a  second  look  examination.
• The  problem  of  the  radiopathological  correlation  of
MRI-guided  biopsies  is  due  to  the  transitory  nature
of  the  MRI  signal,  generated  by  the  injection  of  a
paramagnetic  contrast  agent,  which  does  not  allowsamples.
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Technique
• The  quality  of  targeting  is  of  fundamental
importance,  with  the  insertion  of  a  clip  at  the
end  of  the  procedure.
• The  pathologist  must  be  provided  with  a  sufﬁcient
quantity  of  tissue  (18  11-gauge  biopsies)  together
with  information  on  the  location,  the  nature  and
BI-RADS  classiﬁcation  of  the  lesion.
Results
• Validation  of  the  procedure  is  based  on  conﬁrming
the  accuracy  of  targeting  and  on  concordance  of  the
pathological  result  obtained.
• The  pathologist  should  ﬁnd  that  the  lesion
corresponding  to  the  signal  can  be  distinguished
from  normal  tissue.
• Malignant  results  and  high-risk  lesions  must  undergo
additional  surgery;  benign,  concordant  results
require  longer-term  monitoring;  discordant  results
with  a  suspect  image  and  benign  histology  results
should  lead  to  another  biopsy  or  surgery.  If  the  results
are  benign  but  not  very  speciﬁc,  a  follow-up  MRI
• Is this  result  concordant?  If  the  patient  undergoes  surgery,
what  is  the  basic  aspect  to  look  for  in  the  surgical
histopathology  report?
Answers
1.  Faced  with  this  image  of  distortion  discovered  on
tomosynthesis  examination,  a  breast  MRI  is  recom-
mended.  This  type  of  image  requires  additional  percu-
taneous  biopsy  or  surgical  exploration  without  fail,  and
currently  there  is  limited  access  to  tomosynthesis-guided
biopsy.  Percutaneous  biopsy  should  be  performed  when-
ever  possible  preoperatively.  Breast  MRI  is  an  additional
imaging  technique,  which  can  be  used  where  there  is  any
difﬁculty  with  conventional  imaging.  In  post-menopausal
women,  its  negative  predictive  value  is  excellent.  The
patient’s  breast  MRI  (Fig.  21),  interpretation  of  which
was  hindered  by  symmetrical,  bilateral,  micropunctate,
masking  glandular  enhancement,  detected  a  mass  in
the  area  corresponding  to  the  abnormality  detected  by
tomosynthesis  (concordance  on  the  site  of  the  lesions).
2.  The  BI-RADS  classiﬁcation  is  5  because  the  mass  is  of
irregular  shape  and  has  spiculated  margins.  The  PPV
of  masses  with  spiculated  margins  is  high  and  justiﬁes
this  classiﬁcation.  MRI-guided  biopsy  is  therefore  pro-
posed.  The  biopsy  is  performed  with  a  clip  inserted  at
the  end  of  the  procedure  and  the  biopsy  cavity  checked
in  the  three  planes.  Targeting  was  considered  correct.
The  histopathological  result  was  a grade  II  micropapillary
adenocarcinoma  (Fig.  22).
3.  This  result  is  concordant,  with  suspect  imaging  and
malignant  histology.  Surgery  (lumpectomy  and  sentinel
lymph  node  technique)  should  be  carried  out  after  pre-
operative  location  of  the  clip  with  a  hookwire.  This
was  performed  stereotactically.  Surgical  histopathology
did  not  reveal  any  residual  carcinomatous  lesion  but
the  biopsy  scar  was  found,  evidence  that  the  surgery
occurred  in  the  area  previously  biopsied.  It  is  essential
to  verify  this,  particularly  if  there  is  no  residual  tumor.
The  two  sentinel  lymph  nodes  were  negative.should  be  performed  after  6  months.
Clinical case
A  screening  mammogram  was  performed  on  a  55  year-
old,  post-menopausal  woman,  with  no  personal  or  familial
risk  factors.  There  was  a  doubt  in  this  examination  about
an  asymmetric  focal  density  in  the  left  breast,  on  a
mediolateral  oblique  projection  that  justiﬁed  an  additional
examination  with  a  lateral  projection  and  localized  images,
where  the  image  was  negative.
An  ultrasound  examination  centered  on  the  mammo-
graphic  abnormality  was  negative.
Additional  tomosynthesis  was  performed,  which  detected
an  image  of  left  lateral  distortion  (Fig.  20).
Questions• What  do  you  do?
• What  is  the  MRI  BI-RADS  classiﬁcation  of  this  lesion  and
how  do  you  react?
Figure 20. Tomosynthesis image: axial slice of the left breast
showing an image of lateral distortion (circle).
Figure 21. Contrast-enhanced breast MRI and subtraction: axial
slice. Contrast uptake of left lateral mass with spiculated margins
(arrow).
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Figure 22. HES × 10 histological section corresponding to the
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reast: grade II micropapillary adenocarcinoma.
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